Amyris Inc
(STU:3A01)
€
0.055
0 (0%)
Market Cap: 692,000.00
Enterprise Value: 951.03 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 0/100 Amyris Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Aug 10, 2022 / 10:00PM GMT
Release Date Price:
€3.44
(+67.83%)
John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate
Hi, I'm John Sourbeer, Life Science Analyst at UBS. Joining me on stage today is my associate (inaudible). He's a PhD and a self-described R&D guy, so it's a great addition to a conversation with another R&D guy. Today from Amyris, we have Sunil Chandran. Welcome.
Sunil Chandran
Amyris, Inc. - President of Research & Development
Thank you, John. Glad to be here.
Questions & Answers
John Newton Sourbeer
UBS Investment Bank, Research Division - Equity Research Associate
Great. Maybe just to start off on some of the Clean Beauty, it's really rapidly gaining momentum. From a high level, where does Amyris play in the movement? And what has been the customer feedback? And then how do you educate customers on this new kind of segment within beauty?
Sunil Chandran
Amyris, Inc. - President of Research & Development
Our technology just allows us to naturally play
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot